Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Turning Point Therapeutics Inc (TPTX)

Turning Point Therapeutics Inc (TPTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,727,930
  • Shares Outstanding, K 49,666
  • Annual Sales, $ 30,830 K
  • Annual Income, $ -236,550 K
  • 60-Month Beta 0.84
  • Price/Sales 121.26
  • Price/Cash Flow N/A
  • Price/Book 4.19
Trade TPTX with:

Options Overview Details

View History
  • Implied Volatility 9.61% ( -1.01%)
  • Historical Volatility 229.75%
  • IV Percentile 2%
  • IV Rank 1.50%
  • IV High 131.21% on 05/25/22
  • IV Low 7.76% on 06/15/22
  • Put/Call Vol Ratio 9.50
  • Today's Volume 210
  • Volume Avg (30-Day) 1,868
  • Put/Call OI Ratio 4.54
  • Today's Open Interest 17,642
  • Open Int (30-Day) 18,259

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.78
  • Number of Estimates 7
  • High Estimate -1.55
  • Low Estimate -2.16
  • Prior Year -1.14
  • Growth Rate Est. (year over year) -56.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.26 +132.67%
on 06/02/22
75.44 -0.50%
on 06/22/22
+38.90 (+107.58%)
since 05/27/22
3-Month
23.94 +213.47%
on 04/11/22
75.44 -0.50%
on 06/22/22
+46.81 (+165.70%)
since 03/28/22
52-Week
23.77 +215.78%
on 03/15/22
82.20 -8.69%
on 09/02/21
-1.46 (-1.91%)
since 06/28/21

Most Recent Stories

More News
SHAREHOLDER ALERT: Weiss Law Reminds MBII, VMW, TPTX, and HMTV Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

MBII : 1.0600 (+4.95%)
VMW : 116.25 (-1.20%)
TPTX : 75.06 (-0.28%)
HMTV : 7.79 (-1.77%)
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies

HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company...

TPTX : 75.06 (-0.28%)
SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPTX, DRE, ELSE, PLD

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TPTX : 75.06 (-0.28%)
DRE : 55.60 (-1.01%)
ELSE : 6.09 (+2.70%)
PLD : 118.96 (-1.04%)
SHAREHOLDER ALERT: Weiss Law Reminds TPTX, PCSB, SREV, and HMTV Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

TPTX : 75.06 (-0.28%)
PCSB : 19.07 (-0.57%)
SREV : 1.4500 (-0.68%)
HMTV : 7.79 (-1.77%)
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

BMY : 78.70 (-1.60%)
MRK : 91.89 (-2.67%)
ALKS : 30.39 (+2.08%)
TPTX : 75.06 (-0.28%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PCSB, TPTX, MUDS, CTT

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PCSB : 19.07 (-0.57%)
TPTX : 75.06 (-0.28%)
MUDS : 10.08 (unch)
CTT : 10.04 (-2.71%)
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

REGN : 594.42 (-1.32%)
BMY : 78.70 (-1.60%)
NVAX : 51.06 (-5.13%)
MRTX : 68.50 (-1.67%)
TPTX : 75.06 (-0.28%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VMW, TPTX, CTT, CTEK

NEW YORK, NY / ACCESSWIRE / June 9, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

VMW : 116.25 (-1.20%)
TPTX : 75.06 (-0.28%)
CTT : 10.04 (-2.71%)
CTEK : 1.2600 (-0.79%)
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

REGN : 594.42 (-1.32%)
BMY : 78.70 (-1.60%)
NVAX : 51.06 (-5.13%)
MRTX : 68.50 (-1.67%)
TPTX : 75.06 (-0.28%)
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

BMY : 78.70 (-1.60%)
MRK : 91.89 (-2.67%)
ALKS : 30.39 (+2.08%)
TPTX : 75.06 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their internally developed and wholly owned pipeline of next-generation...

See More

Key Turning Points

3rd Resistance Point 75.49
2nd Resistance Point 75.41
1st Resistance Point 75.23
Last Price 75.06
1st Support Level 74.97
2nd Support Level 74.89
3rd Support Level 74.71

See More

52-Week High 82.20
Last Price 75.06
Fibonacci 61.8% 59.88
Fibonacci 50% 52.99
Fibonacci 38.2% 46.09
52-Week Low 23.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar